Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial
O. Sitbon (Paris, France), J. Bosch (Barcelona, Spain), E. Cottreel (Allschwil, Switzerland), P. De Groote (Lille, France), M. Hoeper (Hannover, Germany), M. Krowka (Rochester, United States of America), N. Martin (Allschwil, Switzerland), L. Savale (Paris, France), N. Kim (La Jolla, United States of America)
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Sitbon (Paris, France), J. Bosch (Barcelona, Spain), E. Cottreel (Allschwil, Switzerland), P. De Groote (Lille, France), M. Hoeper (Hannover, Germany), M. Krowka (Rochester, United States of America), N. Martin (Allschwil, Switzerland), L. Savale (Paris, France), N. Kim (La Jolla, United States of America). Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial. 267
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: